Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (489)

« Back to Publications

Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.

Matthews DR., (2024), Diabetes Obes Metab, 26 Suppl 5, 3 - 4

Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.

Avgerinos I. et al, (2023), Diabetes Obes Metab, 25, 3020 - 3029

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Karagiannis T. et al, (2022), Diabetologia, 65, 1251 - 1261

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.

Yu J. et al, (2022), Cardiovasc Res, 118, 1103 - 1114

Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.

Avgerinos I. et al, (2022), Diabetes Obes Metab, 24, 106 - 114

Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.

Tremblay J. et al, (2021), Diabetologia, 64, 2355 - 2356

Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.

Avgerinos I. et al, (2021), Diabetes Obes Metab, 23, 2395 - 2401

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.

Tremblay J. et al, (2021), Diabetologia, 64, 2012 - 2025

Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.

Tsapas A. et al, (2021), Diabetes Obes Metab, 23, 2116 - 2124

Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.

Avgerinos I. et al, (2021), Diabetes Obes Metab, 23, 822 - 831

Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study.

Chan JCN. et al, (2021), Diabetes Obes Metab, 23, 245 - 251

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.

Tsapas A. et al, (2021), Ann Intern Med, 174

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.

Matthews D. et al, (2020), Diabetes Ther, 11, 2465 - 2476

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.

Matthews DR. et al, (2020), Diabetes Obes Metab, 22, 2199 - 2203

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Tsapas A. et al, (2020), Ann Intern Med, 173, 278 - 286

Load More

1
2
3
4
5
6
7
...
»